18 Aug KneeMD™ to be Featured at 8th Annual Park City Hip & Knee Symposium
Clinically-proven recovery and rehabilitation device essential for patients with knee pain and extension deficit
SALT LAKE CITY–(BUSINESS WIRE)–Promotus, manufacturer of the patient-controlled knee extension device KneeMD™, is proud to be a sponsor of the 8th Annual Park City Hip & Knee (PCHK) Symposium in Park City, UT from August 18-20, 2022. Throughout the in-person event, Promotus invites all attendees to visit their table to learn more about how KneeMD is improving outcomes and increasing patient access to an essential tool for full knee recovery and rehabilitation.
“Historically, the challenge for clinicians and patients alike has been gaining reliable access to devices that are clinically proven to address the critical issue of extension deficit,” says Ron Heffernan, Managing Partner at Promotus investor Mountain Pacific Venture Partners. “Promotus has developed a unique approach that empowers clinics to prescribe KneeMD to any patient who needs it—for as long as they need it—without any interruption to their current workflow.”
Over 60 million Americans are living with knee osteoarthritis (OA), a degenerative joint disease that typically results from wear and tear and progressive loss of cartilage, the natural cushioning between joints. Knee OA leads to pain, swelling, stiffness, and decreased mobility and may eventually require total knee arthroplasty (TKA), a surgical procedure in which the knee joint is replaced with a prosthetic joint. By 2030, it is expected that more than 3.5 million TKAs will be performed annually in the U.S.
Flexion contracture (FC), a joint that cannot be straightened, is a common complication before and after TKA that affects gait and causes pain, which can result in poor patient outcomes and decreased satisfaction. A clinical trial conducted at Anne Arundel Medical Center and published in Current Orthopedic Practice found that patients with preoperative FC who used KneeMD both before and after TKA experienced significant improvements in extension prior to surgery and more rapid improvements in both objective and patient-reported outcome measures post-surgery.
“KneeMD is clinically proven to improve range of motion when used before and after total knee replacement,” says Joe Wheeler, National Director, Sales & Development at Promotus. “The orthopedic surgeons we have been working with are now recommending prehab with KneeMD for all their TKA patients.”
KneeMD has also been adopted by pain management and regeneration clinics that offer non-surgical treatment options to patients with chronic knee pain or extension deficit. A growing number of professional sports teams are using KneeMD as a stretching device to help improve performance and minimize the risk of injury.
About Promotus
Promotus, a privately held medical device company based in Salt Lake City, UT, is dedicated to helping people move forward and get all the way back to living life to the fullest. Promotus’ flagship product, KneeMD, was co-developed by Dr. Richard Steadman, internationally-renowned sports medicine orthopedic surgeon, founder and Chairman Emeritus of The Steadman Clinic, and founder and Co-Chairman of the Steadman Philippon Research Institute, a world leader in orthopedic research and education. KneeMD is a clinically-proven, patient-controlled knee recovery and rehabilitation device for patients with chronic knee pain or extension deficits. Learn more at www.kneemd.co.
Contacts
Joe Wheeler
Promotus
815-245-1047
JWheeler@AlterraMedical.com
SOURCE: KneeMD, Business Wire, August 16 2022.
To find out more news from the industry head over to our news section – orthocg.com/news